Different approach to conserving therapy of uterine fibroids in women of reproductive age

• Main Authors: A N Plekhanov, N A Tatarova, Yu S Shishkina
• Format: Article
• Language: Russian
• Published: IP Berlin A.V. 2015-04-01
• Series: Гинекология
• Subjects: uterine fibroids; myomectomy; agonists of gonadotropin-releasing hormone; ulipristal acetate
• Online Access: https://gynecology.orscience.ru/2079-5831/article/viewFile/28451/pdf

The aim of the study was to evaluate the effectiveness of integrated treatment of uterine fibroids in women of reproductive age; 103 women of reproductive age of minimally invasive myomectomy performed accesses. To prevent a recurrence of fibroids patients in Group 1 as adjuvant therapy was administered agonist of gonadotropin-releasing hormone (buserelin) prolonged action for 4-6 months, patients in group 2 did not receive anti-relapse therapy, patients of group 3 as neoadjuvant ulipristal acetate therapy received. An assessment of long-term effects in all groups of patients. The criteria for the effectiveness of treatment were: frequency of recurrence of fibroids, reproductive and normalization of menstrual function. The result is a significant increase in the recurrence of uterine fibroids in the group receiving no adjuvant therapy (5,2% vs 25%).